Generics and biosimilars in oncology

I. A. Gopienko, E. A. Ushkalova, S. K. Zyryanov
2020 KaÄ?estvennaâ kliniÄ?eskaâ praktika  
Cancer-related morbidity and mortality have been increasing worldwide including in Russia. In recent decades, many innovative antineoplastic pharma products have been launched in the international pharmaceutical market; however, their high price has resulted in significant increase in the cost of treatment and in its inaccessibility for a considerable percentage of patients not only in the countries experiencing low economic growth, but also in those with a high level of economic development.
more » ... omic development. One of the most effective ways of reducing the cost of pharmacotherapy is replacement of innovation medications after the expiration of the patent with their generics and biosimilars. In this article the authors discuss the cost of oncopathology pharmacotherapy with original drugs and their generics and also the factors that affect cost-effectiveness of generics and biosimilars in oncology.
doaj:3d4eb84284044eda9236ccaa8520868f fatcat:lwppcuq73fd4lau532xo6acatm